A VHH library refers to a collection of single-domain antibodies, also known as nanobodies or VHHs. These antibodies are derived from camelids such as alpacas, camels, and llamas. Uniquely, VHHs are the smallest naturally derived antigen-binding fragments. Their small size, stability, and solubility make them attractive for various research and therapeutic applications.
Creation of a VHH Library
The generation of a VHH library starts with isolating the genes encoding VHH domains from the B cells of camelids. This is usually done after immunizing the animal with a target antigen. Once the genetic material is isolated, the VHH-encoding genes are cloned into a display platform, such as phage display or yeast display systems, which allows the VHH proteins to be presented on the surface of the phage or yeast.
This setup creates a vast library of VHH variants with potentially different binding affinities and specificities for the target antigen. The next step involves screening the library through a process called "biopanning," which allows researchers to select high-affinity binders by repeatedly exposing the target antigen to the library.1 Each round narrows down the pool of nanobodies, selecting those with the strongest affinity for the target. This process enables researchers to identify VHHs that bind with high specificity, providing an efficient way to develop antibodies that can be used in diagnostics, therapeutics, or even as research tools.
Related: What Is Phage Display?
Structural Diversity of VHHs
One of the unique aspects of VHHs is their structural diversity, particularly in the complementarity-determining region 3 (CDR3) loop. VHHs can be classified based on the conformation of this CDR3 loop, which is critical for antigen binding. Researchers have categorized VHH structures into three primary conformations: Upright, Half-Roll, and Roll.2 These conformations play a significant role in determining how the nanobody will interact with its target antigen.
The CDR2 loop is also important in shaping the CDR3 structure. Studies, including those by Murakami, suggest that variations in the length of the CDR2 loop influence the final conformation of the CDR3 loop. This structural relationship provides a more refined understanding of how VHHs achieve their binding specificities. Such knowledge is vital for antibody engineering, allowing scientists to tweak nanobody structures for better performance, whether that be in terms of target affinity, stability, or function in complex environments.
Related: What is Antibody Engineering?
Muyldermans S. (2013). Nanobodies: natural single-domain antibodies. Annual review of biochemistry, 82, 775–797. https://doi.org/10.1146/annurev-biochem-063011-092449
Murakami, T., Kumachi, S., Matsunaga, Y., Sato, M., Wakabayashi-Nakao, K., Masaki, H., Yonehara, R., Motohashi, M., Nemoto, N., & Tsuchiya, M. (2022). Construction of a Humanized Artificial VHH Library Reproducing Structural Features of Camelid VHHs for Therapeutics. Antibodies, 11(1). https://doi.org/10.3390/antib11010010
Antibody specificity refers to an antibody's ability to selectively bind to a unique epitope on a target antigen while avoiding interactions with unrelated antigens. This property arises from the highly specialized antigen-binding site located in the variable region of the antibody, which determines its unique binding characteristics.
Antibody affinity refers to the strength of the binding interaction between a single antigen epitope and the paratope (binding site) of an antibody. This interaction is a fundamental measure of how well an antibody recognizes its specific antigen target.
Recombinant antibodies are produced using genetic engineering techniques, unlike traditional antibody production, where the immune system generates antibodies without direct control over their sequence. By introducing genes encoding antibody fragments into host cells, such as bacteria or mammalian cells, recombinant antibodies can be expressed, purified, and deployed for applications including research, diagnostics, and therapeutics.
Recombinant antibody expression is a biotechnological process that involves engineering and producing antibodies outside their natural context using recombinant DNA technology.
ScientistとScience Exchangeとのご利用可能です。
